[September 25, 2017]

Saxena White P.A. Announces a Proposed Settlement Involving All Persons who Purchased or Otherwise Acquired Enzymotec Common Stock

The following statement is being issued by Saxena White P.A. in regard to a proposed class action settlement.

LEGAL NOTICE

TO: ALL PERSONS OR ENTITIES (1) WHO PURCHASED OR OTHERWISE ACQUIRED ENZYMOTEC COMMON STOCK FROM SEPTEMBER 27, 2013 TO AUGUST 4, 2014, INCLUSIVE (THE "SETTLEMENT CLASS PERIOD"), AND WERE DAMAGED THEREBY; AND/OR (2) PURCHASED AND/OR CAN TRACE YOUR PURCHASE OF SHARES OF ENZYMOTEC COMMON STOCK ISSUED IN THE INITIAL PUBLIC OFFERING ("IPO") THAT OCCURRED ON (News - Alert) OR ABOUT SEPTEMBER 27, 2013 AND WERE DAMAGED THEREBY; AND/OR (3) PURCHASED AND/OR CAN TRACE YOUR PURCHASE OF SHARES OF ENZYMOTEC COMMON STOCK ISSUED IN THE SECONDARY PUBLIC OFFERING ("SPO") THAT OCCURRED ON OR ABOUT FEBRUARY 27, 2014, AND WERE DAMAGED THEREBY

PLEASE READ THIS NOTICE CAREFULLY, YOUR RIGHTS WILL BE AFFECTED BY A CLASS ACTION LAWSUIT PENDING IN THIS COURT.

YOU ARE HEREBY NOTIFIED, pursuant to Rule 23 of the Federal Rules of Civil Procedure and an Order of the United States District Court for the District of New Jersey (the "Court"), that the above-captioned litigation (the "Litigation") has been certified, for settlement purposes only, as a class action on behalf of the Settlement Class, as set forth in the full printed Notice of Pendency and Proposed Settlement of Class Action (the "Notice").

YOU ARE ALSO NOTIFIED that pursuant to an Order of the Court, a hearing will be held on January 24, 2018, at 10:30 a.m., before the Honorable John Michael Vazquez, United States District Judge, at the Martin Luther King Building & United States Courthouse, 50 Walnut Street, Newark, New Jersey 07101, for the purpose of determining (1) whether the proposed settlement of the Action for the sum of $6,500,000.00 in cash should be approved by the Court as fair, reasonable, and adequate, which would result in this Litigation being dismissed with prejudice against the Released Persons¹ as set forth in the Stipulation of Settlement dated March 29, 2017; (2) whether the Plan of Allocation of settlement proceeds is fair, reasonable, and adequate and therefore should be approved; and (3) whether the application for fees and expenses in connection with this Litigation should be approved.

If you purchased or otherwise acquired Enzymotec common stock, your rights may be affected by this Litigation and the settlement thereof. If you have not received a detailed Notice of Pendency and Proposed Settlement of Class Action and a copy of the Proof of Claim and Release Form, you may obtain copies by writing to Enzymotec Ltd. Securities Litigation, Claims Administrator, Epiq Systems, Inc., PO Box (News - Alert) 4079 Portland, OR 97208-4079, or by downloading this information at www.EnzymotecSecuritiesLitigation.com.

If you are a Settlement Class Member, in order to share in the distribution of the Net Settlement Fund, you must submit a Proof of Claim and Release Form postmarked no later than December 26, 2017, establishing that you are entitled to a recovery.

You will be bound by any judgment rendered in the Litigation unless you request to be excluded, in writing, to the above address, postmarked by January 3, 2018.

Any objection to any aspect of the settlement must be filed with the Clerk of the Court no later than January 3, 2018, and received by the following no later than January 3, 2018:

If you have any questions about the Settlement, you may call 844-418-6627 or contact Lead Plaintiffs' Counsel at the address listed above. PLEASE DO NOT CONTACT THE COURT REGARDING THIS NOTICE.

¹ Unless otherwise defined herein, all capitalized terms shall have the same meanings as set forth in the Notice of Pendency and Proposed Settlement of Class Action.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170925005042/en/

[ Back To TMCnet.com's Homepage ]